Rejuvenation

The light flashed past, and Norton immediately recovered his kind appearance, with a smile on his mouth, a cheerful appearance.

Jiang Lingyun came back to his senses and immediately said, "Mr. Norton, I will arrange an appointment with Chen Fei immediately."

After finishing speaking, he paused and said, "It's just that we just talked to Chen Fei, and if we meet again, we might--"

Norton shook his head, waved his hand to interrupt Jiang Lingyun, and said, "Don't be so troublesome."

"Mr. Norton, you--" Jiang Lingyun was a little confused. promise

He smiled and said, "I will visit Chen Fei in person."

"Visit yourself!" Jiang Lingyun was taken aback, surprised, "Mr. Norton, you--"

Norton stood up directly and said, "Go and call for a taxi, let's set off right away!"

………

Chen Fei, who came back after the meeting, said goodbye to Tao Ling and Du Lao. He just returned to the office and sat down. The secretary outside heard a message, "Mr. Chen, is there a guest outside who wants to see you?"

who? "Chen Fei asked.

Calligraphy: "Jiang Lingyun Jiang of Jianghuhai Pharmaceutical."

Jiang Lingyun, why did he come? Chen Fei frowned, wondering in his heart. Bi

After all, their talks just ended not long ago. this

At that time, the secretary added: "There is also a foreigner who says his name is Norton."

Foreigner, Norton! "Chen Fei thought for a while, and found that he didn't know this foreigner named Norton, he couldn't help being a little curious, but he waved his hand, "I don't want to see them, let them leave. "

The secretary takes your head, and then turns around to deliver the news. but

Before the secretary went out, they saw Jiang Lingyun and Norton walking towards this side.

"Sir, you can't—" The secretary quickly tried to stop them.

Jiang Lingyun shouted coldly: "I want to see you Mr. Chen!" Then he stretched out his hand and pushed the secretary away.

Upon seeing this, Chen Fei couldn't help crying coldly, and said, "Mr. Chen, this is not your quack, it's better to converge in your behavior."

While speaking, Chen Fei waved his arm directly, sending out an invisible vigor, and directly knocked Jiang Lingyun back.

Jiang Lingyun staggered a few times and almost didn't fall.

Suddenly, his face was gloomy, with anger on his face, he stared at Chen Fei fiercely, "Chen Fei, do you dare to do it to me!" Chen

Fei Leng said: "This is my office. You broke in. This is already the lightest punishment. Otherwise, there are even more ruthless things. Does Jiang always want to try?"

"You--" Jiang Lingyun was furious and couldn't help but explode.

But at this time, Norton stood up with a smile, and directly said to Chen Fei in Chinese: "Mr. Chen, sorry, we are reckless."

Now, I am visiting you formally, Mr. Chen, don’t you know that Mr. Chen is convenient to see us? "While speaking, Norton handed a business card to the secretary. Secret

Shu took the business card in front of Chen Fei, and Chen Fei glanced at the content on the card.

When his eyes fell on the title of "General Manager of Bald Eagle Pharmaceutical Asia Region", his eyes moved involuntarily, and his eyes turned to Norton. promise

With a sudden smile, he looked at Chen Fei with an extremely confident look.

Chen Fei was silent for a while, then looked at Norton and said, "What is the matter with you, please tell me directly." Wen

That said, Jiang Lingyun couldn't help being furious, and shouted to Chen Fei: "Chen Fei, what is your attitude?"

Mr. Norton is a high-level executive of Bald Eagle Pharmaceuticals, you should be so negligent—"

Chen Fei said coldly: "I don't care if he is a bald eagle or a black-headed eagle. This is my company. If you want to say something, just say it. If you don't say it, get out."

"You--" Jiang Lingyun pointed at Chen Fei, furious.

On the contrary, Norton, still smiling, stopped Jiang Lingyun, then looked at Chen Fei, and said, "Since Mr. Chen said so, then I will say it straight."

We, Bald Eagle Pharmaceuticals, would like to cooperate with Mr. Chen. The content of the cooperation is the ephedra oral liquid that Mr. Chen has just developed. We think--"

Hearing this, Chen Fei frowned, waved his hand to interrupt Norton's words, and said: "If it is the acquisition of the patent of ephedra oral liquid, then needless to say, I will not agree to it."

He suddenly smiled and said, "Mr. Chen, don't rush to refuse. Why not listen to our terms?"

No matter what the conditions are, I will not agree to it. "Chen Fei waved his hand.

Upon seeing this, Jiang Lingyun said angrily: "Chen Fei, this is Mr. Norton, it is Bald Eagle Pharmaceutical, this is your opportunity, you--"

He stopped Jiang Lingyun and said to Chen Fei: "I know that Chen is always a smart person, and I absolutely understand the potential of ephedra oral liquid. So, I won’t talk about those false ones. I’ll just say that, our Bald Eagle Pharmaceutical wants ephedra oral solution. Liquid patent——""

This can't be—" Chen Fei waved his hand. No

After Chen Fei finished speaking, Norton said: "We are not going to buy out the patent of ephedra oral liquid, but we will cooperate with you, Mr. Chen, through the sharing model."

"As long as you agree with Mr. Chen, our Bald Eagle Pharmaceuticals will immediately pay Mr. Chen 100 million U.S. dollars. Later, Mr. Chen can also get 5% of the profit of the drug." Listen

Under this condition, Jiang Lingyun was shocked before Chen Fei responded. he

People in the pharmaceutical industry naturally understand the value of Norton's conditions. want

I know that in the pharmaceutical industry, many major laboratories and scientists around the world develop a lot of patented drugs every year, but because of the lack of production and promotion conditions. These scientists and laboratories often sell their research patent results to major pharmaceutical companies. its

In general, there are two ways of selling. One

This is a one-time buyout, which directly transfers the patent right of the drug to the pharmaceutical company, and the pharmaceutical company pays the bill in one lump sum. In the future, the patent rights of the drugs will all belong to the pharmaceutical companies, and have nothing to do with the developers. another

One is the sharing model. The pharmaceutical company first pays a part of the property to the developer, and the subsequent benefit distribution is based on the profit of the drug in a certain proportion. That is, the more medicines are sold, the more profits are shared.

In contrast to these two methods, there is no doubt that the second division model has more potential. After all, once the drug is sold, the developer can get a certain profit from the benefit of every one sold. The ultimate benefit will be more long-term and more lucrative. Much better than a one-time buyout.

Therefore, as long as they are slightly confident in the prospects of their own drugs, they want to use the sharing model to sell patents and obtain more profits.

However, developers know this, and pharmaceutical companies naturally know it.

Therefore, for most drug patents, almost all pharmaceutical companies use the first buyout method. If

If the other party disagrees, they would rather not buy it, or invest their human, material and financial resources to develop similar drugs directly.